A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone

Kyle G. Halvorson, Kazufumi Kubota, Molly A. Sevcik, Theodore H. Lindsay, Julio E. Sotillo, Joseph R. Ghilardi, Thomas J. Rosol, Leila Boustany, David L. Shelton, Patrick W Mantyh

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF-sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain-related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor-induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti-NGF therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor-induced bone cancer pain.

Original languageEnglish (US)
Pages (from-to)9426-9435
Number of pages10
JournalCancer Research
Volume65
Issue number20
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Blocking Antibodies
Nerve Growth Factor
Bone Neoplasms
Prostate
Bone and Bones
Pain
Neoplasms
Osteogenesis
Prostatic Neoplasms
trkA Receptor
Nociceptors
Bone Remodeling
Neuralgia
Osteoblasts
Nerve Fibers
Femur
Morphine
Analgesics
Therapeutics
Animal Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. / Halvorson, Kyle G.; Kubota, Kazufumi; Sevcik, Molly A.; Lindsay, Theodore H.; Sotillo, Julio E.; Ghilardi, Joseph R.; Rosol, Thomas J.; Boustany, Leila; Shelton, David L.; Mantyh, Patrick W.

In: Cancer Research, Vol. 65, No. 20, 15.10.2005, p. 9426-9435.

Research output: Contribution to journalArticle

Halvorson, KG, Kubota, K, Sevcik, MA, Lindsay, TH, Sotillo, JE, Ghilardi, JR, Rosol, TJ, Boustany, L, Shelton, DL & Mantyh, PW 2005, 'A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone', Cancer Research, vol. 65, no. 20, pp. 9426-9435. https://doi.org/10.1158/0008-5472.CAN-05-0826
Halvorson, Kyle G. ; Kubota, Kazufumi ; Sevcik, Molly A. ; Lindsay, Theodore H. ; Sotillo, Julio E. ; Ghilardi, Joseph R. ; Rosol, Thomas J. ; Boustany, Leila ; Shelton, David L. ; Mantyh, Patrick W. / A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. In: Cancer Research. 2005 ; Vol. 65, No. 20. pp. 9426-9435.
@article{9fe6e1abe8f14ec786b8a42616cfcb73,
title = "A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone",
abstract = "Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF-sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain-related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor-induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti-NGF therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor-induced bone cancer pain.",
author = "Halvorson, {Kyle G.} and Kazufumi Kubota and Sevcik, {Molly A.} and Lindsay, {Theodore H.} and Sotillo, {Julio E.} and Ghilardi, {Joseph R.} and Rosol, {Thomas J.} and Leila Boustany and Shelton, {David L.} and Mantyh, {Patrick W}",
year = "2005",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-05-0826",
language = "English (US)",
volume = "65",
pages = "9426--9435",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone

AU - Halvorson, Kyle G.

AU - Kubota, Kazufumi

AU - Sevcik, Molly A.

AU - Lindsay, Theodore H.

AU - Sotillo, Julio E.

AU - Ghilardi, Joseph R.

AU - Rosol, Thomas J.

AU - Boustany, Leila

AU - Shelton, David L.

AU - Mantyh, Patrick W

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF-sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain-related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor-induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti-NGF therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor-induced bone cancer pain.

AB - Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF-sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain-related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor-induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti-NGF therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor-induced bone cancer pain.

UR - http://www.scopus.com/inward/record.url?scp=27144433512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144433512&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0826

DO - 10.1158/0008-5472.CAN-05-0826

M3 - Article

VL - 65

SP - 9426

EP - 9435

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -